BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17047655)

  • 1. Association of decreased mitochondrial DNA content with ovarian cancer progression.
    Wang Y; Liu VW; Xue WC; Cheung AN; Ngan HY
    Br J Cancer; 2006 Oct; 95(8):1087-91. PubMed ID: 17047655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ovarian clear cell carcinomas: RHO GTPases may contribute to explain their singular biologic behavior.
    Canet B; Pons C; Espinosa I; Prat J
    Hum Pathol; 2011 Jun; 42(6):833-9. PubMed ID: 21208644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D; Hirschmann A; Löhrs U; Diebold J
    Gynecol Oncol; 2006 Dec; 103(3):883-7. PubMed ID: 16806438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A quantitative study on nuclear DNA content and morphological parameters in ovarian cystadenocarcinoma].
    Liu C; Zhao Y; Sun X
    Zhonghua Fu Chan Ke Za Zhi; 1995 Dec; 30(12):738-40. PubMed ID: 8728920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues.
    Wang Y; Liu VW; Xue WC; Tsang PC; Cheung AN; Ngan HY
    Gynecol Oncol; 2005 Jul; 98(1):104-10. PubMed ID: 15921730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features.
    Ota T; Gilks CB; Longacre T; Leung PC; Auersperg N
    Reprod Sci; 2007 Sep; 14(6):605-14. PubMed ID: 17959889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
    Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
    APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relation between DNA content in ovarian cystadenoma and its pathohistology].
    Sun ZC
    Zhonghua Fu Chan Ke Za Zhi; 1993 Dec; 28(12):731-3, 760-1. PubMed ID: 8137645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of the methylation status of opioid binding protein/cell adhesion molecule-like gene in ovarian cancer using nested methylation-specific polymerase chain reaction detection.
    Zhou F; Cao X; Liu M; Wang Y; Tao G
    Clin Lab; 2011; 57(5-6):421-4. PubMed ID: 21755835
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Significance and mechanisms of overexpression of PAK1 gene in epithelial ovarian neoplasms].
    Xie D; Yang GF; Chen YQ; Jiang LF; Xiao LZ
    Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):911-4. PubMed ID: 17533742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Different proportions of aneusomic cells in ovarian inclusion cysts associated with serous borderline tumours and serous high-grade carcinomas support different pathogenetic pathways.
    Körner M; Burckhardt E; Mazzucchelli L
    J Pathol; 2005 Sep; 207(1):20-6. PubMed ID: 16021676
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
    Fejzo MS; Dering J; Ginther C; Anderson L; Ramos L; Walsh C; Karlan B; Slamon DJ
    Genes Chromosomes Cancer; 2008 Oct; 47(10):873-83. PubMed ID: 18615678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic significance of cellular DNA content and AgNOR count in ovarian cystadenoma].
    Lu XL; Yi WM; Wang LF
    Ai Zheng; 2003 Jan; 22(1):62-5. PubMed ID: 12561439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Klotho expression in epithelial ovarian cancer and its association with insulin-like growth factors and disease progression.
    Lu L; Katsaros D; Wiley A; de la Longrais IA; Puopolo M; Yu H
    Cancer Invest; 2008 Mar; 26(2):185-92. PubMed ID: 18259951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
    Gurung A; Hung T; Morin J; Gilks CB
    Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger.
    Jensen KC; Mariappan MR; Putcha GV; Husain A; Chun N; Ford JM; Schrijver I; Longacre TA
    Am J Surg Pathol; 2008 Jul; 32(7):1029-37. PubMed ID: 18469706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian cancer is a heterogeneous disease.
    Wang V; Li C; Lin M; Welch W; Bell D; Wong YF; Berkowitz R; Mok SC; Bandera CA
    Cancer Genet Cytogenet; 2005 Sep; 161(2):170-3. PubMed ID: 16102589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interphase fluorescence in situ hybridization studies of ovarian adenocarcinomas using the midisatellite probe.
    Kalir T; Eisberg A; Dottino P; Cohen C
    Gynecol Oncol; 1999 Feb; 72(2):208-14. PubMed ID: 10021303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of ZNF217 in human ovarian cystadenocarcinoma and its clinical significance].
    Sun GQ; Zhong M; Ding YQ; Su GD; Song TR; Yin AL
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Apr; 29(4):685-8. PubMed ID: 19403395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.